/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Galera Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.1379 -0.3259(-32.59%) GRTX at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 0.1354
Highest Today 0.17
Today’s Open 0.1576
Prev. Close 0.2151
52 Week High 3.59
52 Week Low 0.09
Day’s Range: Low 0.1354 High 0.17
52-Week Range: Low 0.09 High 3.59
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

GSA Capital Partners LLP 6.68

Blackstone Inc 3.09

abrdn PLC 1.65

Vanguard Group Inc 0.82

Vanguard Institutional Extnd Mkt Idx Tr 0.82

Geode Capital Management, LLC 0.81

BlackRock Inc 0.66

abrdn Healthcare Opportunities 0.58

Renaissance Technologies Corp 0.58

abrdn Healthcare Investors 0.55

UBS Group AG 0.54

Susquehanna International Group, LLP 0.53

Fidelity Extended Market Index 0.43

abrdn World Healthcare 0.30

Summit Trail Advisors, LLC 0.27

iShares Micro-Cap ETF 0.25

abrdn Life Sciences Investors 0.23

State Street Corporation 0.20

Fidelity Nasdaq Composite Index 0.16

Millennium Management LLC 0.14

Manchester Financial Inc 0.13

Northern Trust Corp 0.13

BlackRock Extended Mkt Composite 0.12

Group One Trading, LP 0.12

BlackRock Extended Equity Market K 0.11

Fidelity Series Total Market Index 0.08

XTX Topco Ltd 0.07

Fidelity Total Market Index 0.07

NT Ext Equity Mkt Idx Fd - NL 0.07

Royal Bank of Canada 0.07

Kestra Advisory Services, LLC 0.06

Good Life Advisors, LLC 0.06

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Level Four Advisory Services, LLC 0.05

Spartan Total Market Index Pool E 0.04

BNYM Mellon SL Market Completion UC1 0.03

Spartan Extended Market Index Pool E 0.03

SSgA U.S. Extended Market Index Class I 0.02

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 11.70 M

PB Ratio 29.3902

PE Ratio 0.0

Enterprise Value 150.50 M

Total Assets 26.14 M

Volume 10752210

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-69683000 -69.7M, FY22:-62222000 -62.2M, FY21:-87728000 -87.7M, FY20:-74218000 -74.2M, FY19:-51930000 -51.9M

Quarterly Revenue Q1/2024:0 0.0M, Q4/2023:88000 0.1M, Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M

Quarterly Profit Q1/2024:-9000 -0.0M, Q4/2023:-127000 -0.1M, Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Net worth Q1/2024:-4381000 -4.4M, Q4/2023:-5587000 -5.6M, Q3/2023:-15073000 -15.1M, Q2/2023:-20712000 -20.7M, Q1/2023:-25762000 -25.8M

Fund house & investment objective

Company Information Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Dr. J. Mel Sorensen M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow